Neurocrine Biosciences Inc. (NBIX)

101.58
0.46 0.45
NASDAQ : Health Technology
Prev Close 101.12
Open 101.27
Day Low/High 100.89 / 102.36
52 Wk Low/High 64.72 / 125.59
Volume 574.11K
Avg Volume 651.60K
Exchange NASDAQ
Shares Outstanding 91.58M
Market Cap 9.29B
EPS 0.20
P/E Ratio 507.05
Div & Yield N.A. (N.A)
JPMorgan Likes These 5 Biotech Stocks

JPMorgan Likes These 5 Biotech Stocks

Shares of biotech stocks have been volatile this year, but the sector is still outperforming the broader markets. Here's JPMorgan's top biotech picks coming out of earnings season.

Insider Trading Alert - NBIX, HELE And FB Traded By Insiders

Insider Trading Alert - NBIX, HELE And FB Traded By Insiders

Stocks with insider trader activity include NBIX, HELE and FB

Perilous Reversal Stock: Neurocrine Biosciences (NBIX)

Perilous Reversal Stock: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "perilous reversal" (up big yesterday but down big today) candidate

Neurocrine Biosciences (NBIX) Stock Spikes on Positive Phase 3 Results

Neurocrine Biosciences (NBIX) Stock Spikes on Positive Phase 3 Results

Neurocrine Biosciences (NBIX) shares are up over 10% after the company announced positive test results of its tardive dyskinesia treatment candidate.

Pre-Market Activity Shows Heavy Volume And Movement For Neurocrine Biosciences (NBIX)

Pre-Market Activity Shows Heavy Volume And Movement For Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a pre-market mover with heavy volume candidate

Neurocrine Biosciences (NBIX) Showing Signs Of Perilous Reversal Today

Neurocrine Biosciences (NBIX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: Neurocrine Biosciences (NBIX)

Strong On High Volume: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Insider Trading Alert - NBIX, TPLM And HURC Traded By Insiders

Insider Trading Alert - NBIX, TPLM And HURC Traded By Insiders

Stocks with insider trader activity include NBIX, TPLM and HURC

Neurocrine Biosciences (NBIX) Showing Signs Of Being Water-Logged And Getting Wetter

Neurocrine Biosciences (NBIX) Showing Signs Of Being Water-Logged And Getting Wetter

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Neurocrine Biosciences (NBIX) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up

After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?

Water-Logged And Getting Wetter Stock Of The Day: Neurocrine Biosciences (NBIX)

Water-Logged And Getting Wetter Stock Of The Day: Neurocrine Biosciences (NBIX)

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACM, AMID, CFX, CVRR, EBF, MED, NBIX, TEF, TTEK, UPS Downgrades: AZPN, BCC, ERF, MODN, UNAM Initiations: ADMS, PAYC, PIH Read on to get TheStreet Quant Ratings' detailed report:

Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock

Neurocrine Biosciences (NBIX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a "perilous reversal" (up big yesterday but down big today) candidate

First Week of NBIX June 19th Options Trading

First Week of NBIX June 19th Options Trading

Investors in Neurocrine Biosciences, Inc. saw new options become available this week, for the June 19th expiration.

'Mad Money' Lightning Round: Alcoa Is Doing Everything Right

'Mad Money' Lightning Round: Alcoa Is Doing Everything Right

Cramer says to wait on Neurocrine Biosciences and Cummins and lighten up on Western Digital.

Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference

Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference

It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.

Short Interest In Neurocrine Biosciences Drops 20.6%

Short Interest In Neurocrine Biosciences Drops 20.6%

The most recent short interest data has been released by the NASDAQ for the 02/27/2015 settlement date, which shows a 1,670,167 share decrease in total short interest for Neurocrine Biosciences, Inc. , to 6,432,232, a decrease of 20.61% since 02/13/2015.

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options

Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options

Investors considering a purchase of Neurocrine Biosciences, Inc. stock, but cautious about paying the going market price of $21.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients

Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients

Auspex is expected to seek U.S. approval for SD-809 next year.

2 Big-Volume Biotech Stocks to Trade for Breakouts

2 Big-Volume Biotech Stocks to Trade for Breakouts

These biotech stocks rising on unusual volume are within range of triggering breakout trades.

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks

It's not the hedge fund mogul you expect.

NBIX Crosses Above Key Moving Average Level

NBIX Crosses Above Key Moving Average Level

In trading on Wednesday, shares of Neurocrine Biosciences, Inc. crossed above their 200 day moving average of $13.82, changing hands as high as $14.17 per share.

Commit To Purchase Neurocrine Biosciences At $12, Earn 27.6% Annualized Using Options

Commit To Purchase Neurocrine Biosciences At $12, Earn 27.6% Annualized Using Options

Investors eyeing a purchase of Neurocrine Biosciences, Inc. shares, but tentative about paying the going market price of $14.56/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Bullish Two Hundred Day Moving Average Cross - NBIX

Bullish Two Hundred Day Moving Average Cross - NBIX

In trading on Thursday, shares of Neurocrine Biosciences, Inc. crossed above their 200 day moving average of $13.48, changing hands as high as $13.99 per share.

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences Inc. Stock Downgraded (NBIX)

Neurocrine Biosciences (Nasdaq:NBIX) has been downgraded by TheStreet Ratings from from a hold to sell.

Ratings Changes Today

Upgrades: ARCO, AVB, BCOM, CVRR, GPRC, NEOG, RAND, TEU Downgrades: CCU, EVK, MFNC, NBIX, NMRX, NYNY, PEGA, RTI, TRK Initiations: DARA, KIOR, ORC Read on to get TheStreet Quant Ratings' detailed report:

Neurocrine Biosciences is Now Oversold (NBIX)

Neurocrine Biosciences is Now Oversold (NBIX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: C+ (Hold)